Madrigal Pharmaceuticals, Inc. (MDGL) announced that the United States Patent and Trademark Office has issued a Notice of Allowance covering the FDA-approved use of Rezdiffra or resmetirom, the first and only FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The company noted that the U.S. patent scheduled to issue from this application provides protection through Sept. 30, 2044, and will be listed in the FDA's Orange Book.
"This issuance marks a pivotal milestone in our long-term Rezdiffra strategy," said Bill Sibold, Chief Executive Officer of Madrigal.
Shares of Madrigal Pharmaceuticals, Inc. are up 6% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.